ASO Author Reflections: Towards Consensus on Resectability Assessments and Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases.
作者信息
Bond Marinde J G, Punt Cornelis J A, Swijnenburg Rutger-Jan
机构信息
Department of Epidemiology, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands.
Department of Surgery, Amsterdam UMC, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
出版信息
Ann Surg Oncol. 2023 Sep;30(9):5386-5387. doi: 10.1245/s10434-023-13513-4. Epub 2023 Apr 21.
Abstract
摘要
相似文献
1
ASO Author Reflections: Towards Consensus on Resectability Assessments and Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases.ASO作者反思：迈向对初始不可切除的结直肠癌肝转移患者可切除性评估和局部治疗规划的共识
Ann Surg Oncol. 2023 Sep;30(9):5386-5387. doi: 10.1245/s10434-023-13513-4. Epub 2023 Apr 21.
2
ASO Author Reflections: At the Crossroad-Liver Transplantation for Unresectable Colorectal Liver Metastases in the United States.ASO作者反思：在美国，不可切除的结直肠癌肝转移患者的肝移植之路
Ann Surg Oncol. 2023 May;30(5):2778-2779. doi: 10.1245/s10434-023-13169-0. Epub 2023 Jan 30.
3
The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.诱导全身治疗后结直肠癌肝转移技术解剖可切除性评估中肿瘤生物学因素的作用：荷兰 CAIRO5 试验分析。
Eur J Cancer. 2023 Apr;183:49-59. doi: 10.1016/j.ejca.2023.01.013. Epub 2023 Jan 31.
4
Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group.外科医生之间在初始不可切除的结直肠癌肝转移患者局部治疗计划中的差异：荷兰结直肠癌组肝脏专家组的分析。
Ann Surg Oncol. 2023 Sep;30(9):5376-5385. doi: 10.1245/s10434-023-13510-7. Epub 2023 Apr 28.
5
ASO Author Reflections: Patients with Recurrence Amenable to Local Therapy for Colorectal Liver Metastases May Experience Improved Survival.ASO作者反思：可接受局部治疗的复发性结直肠癌肝转移患者可能生存期得到改善。
Ann Surg Oncol. 2024 Apr;31(4):2600-2601. doi: 10.1245/s10434-024-15005-5. Epub 2024 Feb 7.
6
ASO Author Reflections: Circulating Tumor Cell Count is a Prognostic Factor in Patients with Resected Colorectal Cancer Liver Metastases.ASO作者反思：循环肿瘤细胞计数是切除的结直肠癌肝转移患者的一个预后因素。
Ann Surg Oncol. 2019 Dec;26(Suppl 3):842. doi: 10.1245/s10434-019-08005-3. Epub 2019 Oct 28.
7
ASO Author Reflections: The Role of CEA Optimizing Perioperative Treatments for Colorectal Cancer with Liver Metastases.ASO作者反思：癌胚抗原在优化结直肠癌肝转移围手术期治疗中的作用
Ann Surg Oncol. 2022 Dec;29(13):8394-8395. doi: 10.1245/s10434-022-12372-9. Epub 2022 Aug 6.
8
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).初始不可切除的单纯肝转移结直肠癌患者的治疗策略，荷兰结直肠癌组（DCCG）随机3期CAIRO5研究的研究方案
BMC Cancer. 2015 May 6;15:365. doi: 10.1186/s12885-015-1323-9.
9
ASO Author Reflections: Peri-operative Chemotherapy for Resectable Colorectal Liver Metastases.ASO作者反思：可切除结直肠癌肝转移的围手术期化疗
Ann Surg Oncol. 2022 Oct;29(11):6843-6844. doi: 10.1245/s10434-022-12176-x. Epub 2022 Jul 13.
10
ASO Author Reflections: Surgical Strategy for Bilobar Colorectal Liver Metastases with Vascular Invasion.《美国外科医师学会（ASO）作者反思：伴有血管侵犯的双叶结直肠癌肝转移的手术策略》
Ann Surg Oncol. 2023 May;30(5):2841-2842. doi: 10.1245/s10434-023-13257-1. Epub 2023 Feb 20.
本文引用的文献
1
Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group.外科医生之间在初始不可切除的结直肠癌肝转移患者局部治疗计划中的差异：荷兰结直肠癌组肝脏专家组的分析。
Ann Surg Oncol. 2023 Sep;30(9):5376-5385. doi: 10.1245/s10434-023-13510-7. Epub 2023 Apr 28.
2
The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.诱导全身治疗后结直肠癌肝转移技术解剖可切除性评估中肿瘤生物学因素的作用：荷兰 CAIRO5 试验分析。
Eur J Cancer. 2023 Apr;183:49-59. doi: 10.1016/j.ejca.2023.01.013. Epub 2023 Jan 31.
3
Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.结直肠癌肝转移单纯化疗联合靶向药物的转化策略：系统评价。
Eur J Cancer. 2020 Dec;141:225-238. doi: 10.1016/j.ejca.2020.09.037. Epub 2020 Nov 12.
4
The value of a dedicated multidisciplinary expert panel to assess treatment strategy in patients suffering from colorectal cancer liver metastases.专门的多学科专家小组评估结直肠癌肝转移患者治疗策略的价值。
Surg Oncol. 2020 Dec;35:412-417. doi: 10.1016/j.suronc.2020.09.024. Epub 2020 Sep 29.
5
Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons: A Throw of the Dice?专家肝脏外科医师治疗结直肠肝转移的策略选择：掷骰子？
Ann Surg. 2020 Nov;272(5):715-722. doi: 10.1097/SLA.0000000000004331.
6
Outcomes of Resectability Assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel.荷兰结直肠肿瘤学组肝脏转移专家组可切除性评估的结果。
J Am Coll Surg. 2019 Dec;229(6):523-532.e2. doi: 10.1016/j.jamcollsurg.2019.08.1445. Epub 2019 Sep 11.
7
Effect of specialist decision-making on treatment strategies for colorectal liver metastases.专家决策对结直肠癌肝转移治疗策略的影响。
Br J Surg. 2012 Sep;99(9):1263-9. doi: 10.1002/bjs.8835.
8
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.西妥昔单抗新辅助化疗后结直肠癌肝转移的肿瘤反应和二次可切除性：CELIM 随机 2 期试验。
Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.
Zotero 插件